The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 26, 2007

Filed:

May. 02, 2001
Applicants:

Joseph Loscalzo, Dover, MA (US);

Joseph A. Vita, Hingham, MA (US);

Michael D. Loberg, Boston, MA (US);

Manuel Worcel, Boston, MA (US);

Inventors:

Joseph Loscalzo, Dover, MA (US);

Joseph A. Vita, Hingham, MA (US);

Michael D. Loberg, Boston, MA (US);

Manuel Worcel, Boston, MA (US);

Assignee:

NitroMed, Inc., Lexington, MA (US);

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 38/43 (2006.01); A61K 31/215 (2006.01); A01N 37/12 (2006.01); A01N 33/18 (2006.01);
U.S. Cl.
CPC ...
Abstract

The present invention provides methods of treating or preventing vascular diseases caused by nitric oxide (NO) insufficiency. The methods encompass administering a composition comprising an antioxidant, a compound to treat cardiovascular diseases, a nitrosated compound, a compound that donates, transfers or relases NO, or is a NO synthase substrate, or endogenously stimulates NO synthesis, or stimulates levels of endothelium derived relaxing factor. In the said composition, a hydralazine compound may be an antioxidant, isosorbide mono-or dinitrate may be the compound to donate, transfer, release, or stimulate endogenous NO synthesis. The isorsorbide may also elevate endogenous levels of endotherlium-derived relaxing factor, or be a NO synthase substrate and angiotensin enzyme inhibitor may be nitrosated compound. Disclosed in the invention is also a method to treat, or prevent Renaud's syndrome by administering a therapeutically effective amount of an antioxidant, a NO donor, a nitrosated compound and novel sustained-release formulations (e.g. a transdermal patch).


Find Patent Forward Citations

Loading…